Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

New thinking for education leaders

A Gates Cambridge Scholar has co-authored a new book which is being described by leading educationalists as transforming the way schools think about change. The Pruning Principle offers a new approach to educational leadership, drawing inspiration from horticulture to address the chronic issues of overwork and inefficiency in schools. The authors, Gates Cambridge Scholar Dr Simon […]

A passion for biotech innovation in Africa

Taryn Adams has long been interested in bridging the gap between science and business in order to ensure science has practical, useful applications. Coming from South Africa, she says the innovation that results from linking science and business, particularly in biotech, is still in its early stages, but she feels there is room to make […]

Caught on camera: how we see the world through digital images

Emmanuel Iduma will be one of the first people to do the University of Cambridge’s new PhD in Digital Humanities and he brings a wealth of experience in multimedia to the subject. Emmanuel [2024] is not only an acclaimed writer, but has been fascinated by the role of photography for many years – how photographs […]

Tributes paid to Arif Naveed – ‘a brilliant scholar and an even better human being’

It is with great sadness that the Trust has learned of the death of Gates Cambridge Scholar Arif Naveed [2014]. Arif did his PhD in Education at the University of Cambridge and won the Bill Gates Sr Award in 2018. This is an award nominated by other scholars and their nominations show the impact Arif […]